The demand for glucagon-like peptide-1 (GLP-1) medications for weight loss has surged, in part because there is a large population of patients who could potentially benefit from them. Meanwhile, advocates are concerned about the recent widespread distribution of compounded versions of the drugs. Since compounded versions often expect patients to measure doses from vials and use syringes for delivery—instead of premeasured autoinjector pens—compounded options can lead to dosing errors. But the advantage of compounded GLP1s …
Read More
